Inactive Instrument

News GOLD SWAP OTC Bulletin Board

Stocks

GDSW

US38074W1009

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

07-10	Top Midday Decliners	MT
07-10	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT

All News

Mentions Relevance

07-14	Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform	AQ
07-10	Top Midday Decliners	MT
07-10	Silo Pharma Launches Private Placement to Raise Up to $11.7 Million	MT
07-10	Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
07-09	Silo Pharma, Inc. announced that it has received $4.000015 million in funding	CI
07-07	Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program	AQ
06-29	Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request	AQ
06-29	Silo Pharma Advances SPC-15 PTSD Therapeutic With Drug-Device Robustness Study Ahead Of Planned FDA Type C Meeting Request	CI
06-23	Silo Pharma, Inc. Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-In-Human Clinical Trial	CI
06-23	Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months	MT
06-23	Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial	AQ
06-18	Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement	MT
06-18	Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement	AQ
06-04	Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split	MT
05-14	Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on February 23, 2026.	CI
05-14	Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury	GL
05-07	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury	CI
04-29	Silo Pharma's PTSD program advances as FDA fast-tracks psychedelic therapies for PTSD	RE
04-29	Silo Pharma : PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	PU
04-29	Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	GL
04-29	Silo Pharma, Inc. Announces Its PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD	CI
04-22	Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents	GL
04-22	Silo Pharma, Inc. acquired Qwikagents.com, Qikagents.ai, and Qwikagents.co from Many Ads Inc. for $0.7 million.	CI
04-20	Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics	CI